RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy. (12th October 2011)

• Record Type: Journal Article
• Authors: Yajima, Ichiro; Kumasaka, Mayuko Y.; Thang, Nguyen Dinh; Goto, Yuji; Takeda, Kozue; Yamanoshita, Osamu; Iida, Machiko; Ohgami, Nobutaka; Tamura, Haruka; Kawamoto, Yoshiyuki; Kato, Masashi
• Other Names: Quatresooz Pascale Academic Editor.
• Is Part Of: Dermatology research and practice. Volume 2012(2012)
• Publication Date: 2011-10-12
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; Skin -- Diseases -- Treatment -- Periodicals; 616.5005
• DOI: 10.1155/2012/354191
• Languages: English
• ISSNs: 1687-6105

Abstract

Abstract : Cutaneous malignant melanoma is one of the most serious skin cancers and is highly invasive and markedly resistant to conventional therapy. Melanomagenesis is initially triggered by environmental agents including ultraviolet (UV), which induces genetic/epigenetic alterations in the chromosomes of melanocytes. In human melanomas, the RAS/RAF/MEK/ERK (MAPK) and the PI3K/PTEN/AKT (AKT) signaling pathways are two major signaling pathways and are constitutively activated through genetic alterations. Mutations of RAF, RAS, and PTEN contribute to antiapoptosis, abnormal proliferation, angiogenesis, and invasion for melanoma development and progression. To find better approaches to therapies for patients, understanding these MAPK and AKT signaling mechanisms of melanoma development and progression is important. Here, we review MAPK and AKT signaling networks associated with melanoma development and progression.